4-methyleneglutamine | 62278-77-7

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 4-methyleneglutamine
• 英文别名: (+/-)-2-amino-4-methylene-glutaramic acid；(+/-)-2-Amino-4-methylen-glutaramidsaeure；2-azaniumyl-4-carbamoylpent-4-enoate
• CAS: 62278-77-7
• 化学式: C₆H₁₀N₂O₃
• 分子量: 158.157
• InChiKey: CEVQXWMPODOBRM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -3.6
• 重原子数：
  11
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  106
• 氢给体数：
  3
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  alkaline earth salt of/the/ methylsulfuric acid 在 水 、 sodium carbonate 、 肼 作用下， 生成 4-methyleneglutamine
  参考文献：
  名称：

  炔属化合物的研究。LI部分。γ-亚甲基谷氨酸和γ-亚甲基谷氨酰胺的合成

  摘要：

  DOI：

  10.1039/jr9550003636

文献信息

• NEUROTOXIC AMINO ACID OR NEUROTOXIC DERIVATIVE THEREOF ASSOCIATED WITH NEUROLOGICAL DISORDERS
  申请人：Institute For Ethnomedicine

  公开号：EP1664793A1

  公开（公告）日：2006-06-07
• Neurotoxic amino acid or neurotoxic derivative thereof associated with neurological disorders
  申请人：The Institute for Ethnomedicine

  公开号：EP1860441B1

  公开（公告）日：2011-08-10
• FOAMABLE WATERLESS COMPOSITIONS WITH MODULATING AGENTS
  申请人：Foamix Ltd.

  公开号：EP2097065A2

  公开（公告）日：2009-09-09
• PH-BIOSENSORS BASED ON COMPOUNDS PRODUCED FROM PYRUVIC ACID FOR MAGNETIC RESONANCE IMAGING AND SPECTROSCOPY AND THEIR USES
  申请人：Technische Universität München

  公开号：EP3058375A1

  公开（公告）日：2016-08-24
• SCREENING FOR NEUROTOXIC AMINO ACID ASSOCIATED WITH NEUROLOGICAL DISORDERS
  申请人：Cox A. Paul

  公开号：US20070254315A1

  公开（公告）日：2007-11-01

  Methods for screening for neurological disorders are disclosed. Specifically, methods are disclosed for screening for neurological disorders in a subject by analyzing a tissue sample obtained from the subject for the presence of elevated levels of neurotoxic amino acids or neurotoxic derivatives thereof associated with neurological disorders. In particular, methods are disclosed for diagnosing a neurological disorder in a subject, or predicting the likelihood of developing a neurological disorder in a subject, by determining the levels of β-N-methylamino-L-alanine (BMAA) in a tissue sample obtained from the subject. Methods for screening for environmental factors associated with neurological disorders are disclosed. Methods for inhibiting, treating or preventing neurological disorders are disclosed.